AVH 0.61% $4.95 avita medical inc.

non-dilutive funding

  1. 1,505 Posts.
    lightbulb Created with Sketch. 1868
    The Avita presentation from February 2014 referred to three sources of non-dilutive funding targeted for the September Quarter 2014. Given that a decision has been made to retain non-core assets i.e. respiratory products, the proposed sources of non-dilutive funding now include;
    a) Partnership (out-licencing, large scale distribution)
    b) Clinical Trial Funding (US Government/military)

    Since October has already rolled around, expect something shortly. I'm particularly interested in the opportunity for b).

    Although AFIRM have provided grants in the past, its primary focus upon early stage programs means that clinical trial funding could come from other sources. Compassionate use cases in the US (and around the world) have highlighted the advantages of the use of ReCell in massive burn and wound injuries.

    The U.S. Army Medical Research and Materiel Command comes to mind as a government/military institution which may be interested in driving the modified clinical trial forward. Australian companies have benefited in the past, for instance Neuren Pharmaceuticals have received more than $26m in funding in non-dilutive grants from the USAMRMC as well as regulatory support and technical advice.
 
watchlist Created with Sketch. Add AVH (ASX) to my watchlist
(20min delay)
Last
$4.95
Change
0.030(0.61%)
Mkt cap ! $302.5M
Open High Low Value Volume
$4.96 $5.06 $4.92 $578.7K 115.9K

Buyers (Bids)

No. Vol. Price($)
1 5617 $4.95
 

Sellers (Offers)

Price($) Vol. No.
$4.96 659 1
View Market Depth
Last trade - 16.10pm 28/03/2024 (20 minute delay) ?
Last
$4.95
  Change
0.030 ( 1.02 %)
Open High Low Volume
$5.02 $5.04 $4.93 6504
Last updated 15.18pm 28/03/2024 ?
AVH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.